Ratios in Focus: Analyzing Ionis Pharmaceuticals Inc (IONS)’s Price-to-Cash and Price-to-Free Cash Flow

Beyond market averages, investors seeking exceptional growth focus on the art of stock selection. The right picks can significantly contribute to the expansion of your wealth.

3 Tiny Stocks Primed to Explode The world's greatest investor — Warren Buffett — has a simple formula for making big money in the markets. He buys up valuable assets when they are very cheap. For stock market investors that means buying up cheap small cap stocks like these with huge upside potential.

We've set up an alert service to help smart investors take full advantage of the small cap stocks primed for big returns.

Click here for full details and to join for free
Sponsored

In the latest session, Ionis Pharmaceuticals Inc (NASDAQ: IONS) closed at $47.24 up 2.50% from its previous closing price of $46.09. In other words, the price has increased by $2.50 from its previous closing price. On the day, 1.07 million shares were traded. IONS stock price reached its highest trading level at $47.35 during the session, while it also had its lowest trading level at $45.425.

Ratios:

For a deeper understanding of Ionis Pharmaceuticals Inc’s stock, let’s take a closer look at its various ratios. For the most recent quarter (mrq), Quick Ratio is recorded 7.28 and its Current Ratio is at 7.37. In the meantime, Its Debt-to-Equity ratio is 6.64 whereas as Long-Term Debt/Eq ratio is at 6.49.

On April 10, 2024, Wolfe Research Upgraded its rating to Outperform which previously was Peer Perform but kept the price unchanged to $58.

BofA Securities Upgraded its Neutral to Buy on January 02, 2024, whereas the target price for the stock was revised from $52 to $62.

Insider Transactions:

Additionally, insider trades can be beneficial to investors who want to learn what the management thinks about stock prices in the future. A recent insider transaction in this stock occurred on Jun 17 ’24 when BERTHELSEN SPENCER R sold 16,000 shares for $40.29 per share. The transaction valued at 644,640 led to the insider holds 147,257 shares of the business.

KLEIN JOSEPH III sold 6,000 shares of IONS for $256,277 on May 03 ’24. The Director now owns 0 shares after completing the transaction at $42.71 per share. On Apr 16 ’24, another insider, Baroldi Joseph, who serves as the EVP, Chief Business Officer of the company, sold 4,006 shares for $41.60 each. As a result, the insider received 166,641 and left with 19,631 shares of the company.

Valuation Measures:

Investors should consider key stock statistics when deciding whether to invest or divest. In the wake of the recent closing price, IONS now has a Market Capitalization of 6895386624 and an Enterprise Value of 6659770368. For the stock, the TTM Price-to-Sale (P/S) ratio is 8.87 while its Price-to-Book (P/B) ratio in mrq is 23.24. Its current Enterprise Value per Revenue stands at 8.575 whereas that against EBITDA is -18.781.

Stock Price History:

The Beta on a monthly basis for IONS is 0.40, which has changed by 0.12209022 over the last 52 weeks, in comparison to a change of 0.2553556 over the same period for the S&P500. Over the past 52 weeks, IONS has reached a high of $54.44, while it has fallen to a 52-week low of $35.95. The 50-Day Moving Average of the stock is 15.20%, while the 200-Day Moving Average is calculated to be 3.92%.

Shares Statistics:

For the past three months, IONS has traded an average of 1.23M shares per day and 2146360 over the past ten days. A total of 144.34M shares are outstanding, with a floating share count of 134.19M. Insiders hold about 8.07% of the company’s shares, while institutions hold 96.75% stake in the company. Shares short for IONS as of 1718323200 were 8653199 with a Short Ratio of 7.06, compared to 1715731200 on 8625854. Therefore, it implies a Short% of Shares Outstanding of 8653199 and a Short% of Float of 7.0199996.

Most Popular